TQF3510 (Semaglutide Injection)
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQF3510 (Semaglutide Injection) is one of 6 small molecule programs targeting Weight Management. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Weight Management
#DrugCompanyPhaseTrials
1VK2735
VViking Therapeutics, Inc.
Phase 3
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 1
TQF3510 (Semaglutide Injection)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
Meridia
AAbbott
Preclinical
Febuxostat Tab
XXuhui Central Hospital, Shanghai
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Weight Management1 trial
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06738979·408 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06738979·408 enrolledSources
References
- [1]
- [2]
- [3]
- [4]
Details